Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3...

Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test Waltham, MA, May 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx®...

Exosome Diagnostics and Chesapeake Urology Partner to Evaluate Clinical Value of ExoDx® Prostate(IntelliScore) in First Study Under Novel Evidence Development Collaboration Baltimore, MD and Boston, MA, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics (ExoDx) and Chesapeake Urology announced today that they have initiated a new evidence development study to...